Navigation Links
ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
Date:4/20/2011

cedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2010.  Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Ther
'/>"/>

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S.
2. Knauf Insulation Files Lawsuit to Protect ECOSE® Technology
3. AVAX Technologies, Inc. Files Form 10 With SEC
4. Cempra Pharmaceuticals Profiles the Broad Spectrum and Potent Activity Profile of Solithromycin (CEM-101) at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
5. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
6. China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
7. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Celsis Rapid Detections Updated Drug Master Files (DMFs) Accepted by FDA
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... India , June 19, ... Bharat Book Bureau presents Innovative ... and Formulation Technology Licensing Opportunities ... http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/innovative-drug-delivery-systems-novel-product-and-formulation-technology-licensing-opportunities-for-generic-pharmaceutical-companies.html ) There ... or controlled release drugs approved ...
(Date:6/19/2013)... Express Diagnostics Int’l, Inc., manufacturer of ... it has received Class III medical device license approval ... DrugCheck® NxStep Onsite Drug Screen Cup in Canada. ... device in near-patient settings, such as physicians’ offices. , ... Canada Class III approval for 24 different drugs and ...
(Date:6/18/2013)... In support of Swiss contributions to scientific ... Switzerland in New York is pleased to welcome the ... , to Manhattan. PlanetSolar is in New York ... with scientists on board from the University of Geneva. ... on energy from the sun and eliminates the need ...
(Date:6/18/2013)... DuPont welcomes 48 of the nation’s ... National AgriScience Teachers Ambassador Academy this week (NATAA) at ... , The NATAA “Ag Academy” is a ... special project of the National FFA Foundation ... . The highly recommended agriscience teachers, who are ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3
... German . , Automation makes a business competitive ... small and medium-sized enterprises (SMEs). However, for many SMEs, ... too big or too expensive. SMErobot now promises to ... in small and medium-sized businesses: this EU project is ...
... 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, will announce its fourth ... market open on,Wednesday, March 5, 2008. The Company ... these results later that same day at 10:00 ...
... KOSN ) today reported financial results for the,quarter and year ... and year ended December 31, 2007 were $9.5,million and $28.7 ... and $29.5 million, or $0.13 and $0.88 per share, in ... million and $22.7 million for the quarter and year,ended December ...
Cached Biology Technology:SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 2SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 3SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 2Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 3Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 5Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 6
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
(Date:6/18/2013)... of internationally recognized feline experts including veterinarians and feline ... of Lincoln, U.K. and Dr Ilona Rodan, Director of ... International Society of Feline Medicine (ISFM) and the American ... veterinarians, owners and those working with cats on how ... The new guidelines appear in the Journal of ...
(Date:6/17/2013)... to high levels of air pollution while pregnant were up ... as women who lived in areas with low pollution, according ... (HSPH). It is the first large national study to examine ... "Our findings raise concerns since, depending on the pollutant, 20% ... areas where risk of autism was elevated," said lead author ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... Mont. -- Natural barriers like waterfalls play an important ... National Park, so maintaining those barriers should be a ... four-year study in the park. Park workers might ... the water from rising behind those barriers, said graduate ...
... more than 300 leading European and Chinese scientists have ... in the Peoples Republic of China to present their ... Dragon 2. The Dragon Programme is a joint ... Technology (MOST) of China designed to encourage increased exploitation ...
... (April 24, 2008) The Wildlife Conservation Society (WCS) ... change is affecting populations of a quintessential Arctic denizen: ... the National Park Service, U. S. Geological Survey, and ... already equipped six musk ox with GPS collars to ...
Cached Biology News:Montana State researchers study spread of lake trout in Glacier National Park 2Successful cooperation extends Dragon Program 2Successful cooperation extends Dragon Program 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: